{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:41Z","timestamp":1761518921133,"version":"3.37.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/2.zoppoz.workers.dev:443\/https\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1360,"URL":"https:\/\/2.zoppoz.workers.dev:443\/https\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Biomedical Informatics"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.jbi.2009.05.010","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T08:43:33Z","timestamp":1245228213000},"page":"990-1003","source":"Crossref","is-referenced-by-count":21,"title":["Computing with evidence"],"prefix":"10.1016","volume":"42","author":[{"given":"Richard","family":"Boyce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Kalet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1109\/TITB.2007.890842","article-title":"Modeling drug mechanism knowledge using evidence and truth maintenance","volume":"11","author":"Boyce","year":"2007","journal-title":"IEEE Trans Inform Technol Biomed"},{"issue":"6","key":"10.1016\/j.jbi.2009.05.010_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jbi.2009.05.001","article-title":"Computing with evidence part I: a drug-mechanism evidence taxonomy oriented toward confidence assignment","volume":"42","author":"Boyce","year":"2009","journal-title":"J Biomed Inform"},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jbi.2009.05.010_bib4","unstructured":"R Development Core Team. R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria; 2006. ISBN 3-900051-07-0. Available from: https:\/\/2.zoppoz.workers.dev:443\/http\/www.R-project.org."},{"key":"10.1016\/j.jbi.2009.05.010_bib5","unstructured":"Falissard B. psy: Various procedures used in psychometry. R package version 0.7; 2007."},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5414\/CPP43123","article-title":"Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment","volume":"43","author":"Shi","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jbi.2009.05.010_bib7","unstructured":"Abbot. pce (erythromycin) tablet. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 03\/03\/2008."},{"issue":"1","key":"10.1016\/j.jbi.2009.05.010_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-003-0573-7","article-title":"The effect of erythromycin on the pharmacokinetics of rosuvastatin","volume":"59","author":"Cooper","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jbi.2009.05.010_bib9","unstructured":"Novartis Pharmaceuticals Corporation. lescol (fluvastatin sodium) capsule; lescol XL (fluvastatin sodium) tablet, extended release. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 07\/02\/2008."},{"issue":"1","key":"10.1016\/j.jbi.2009.05.010_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2125.1998.00034.x","article-title":"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin","volume":"46","author":"Kivisto","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jbi.2009.05.010_bib11","unstructured":"Astrazeneca. crestor (Rosuvastatin calcium) tablet, film coated for oral use. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 04\/17\/2008."},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies","volume":"24","author":"Black","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.jbi.2009.05.010_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-002-0508-8","article-title":"The effect of fluconazole on the pharmacokinetics of rosuvastatin","volume":"58","author":"Cooper","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0009-9236(02)17633-8","article-title":"Effect of itraconazole on the pharmacokinetics of rosuvastatin","volume":"73","author":"Cooper","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib15","first-page":"623","article-title":"Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily","volume":"25","author":"Rodrigues","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jbi.2009.05.010_bib16","unstructured":"Squibb B-M. Pravachol (pravastatin sodium) tablet. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 03\/19\/2009."},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0009-9236(98)90176-X","article-title":"Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences","volume":"64","author":"Greenblatt","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jbi.2009.05.010_bib18","first-page":"213","article-title":"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam","volume":"46","author":"Zimmermann","year":"1996","journal-title":"Arzneimittelforschung"},{"issue":"8","key":"10.1016\/j.jbi.2009.05.010_bib19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","article-title":"General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs","volume":"46","author":"Ohno","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbi.2009.05.010_bib20","unstructured":"Internal Authorship. FDA guideline: drug interaction studies\u2014study design, data analysis, and implications for dosing and labeling; 2006. Available from: https:\/\/2.zoppoz.workers.dev:443\/http\/www.fda.gov\/Cber\/gdlns\/interactstud.htm. Last accessed 09\/25\/2006."},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modeling: towards prediction paradise?","volume":"2","author":"van de Waterbeemd","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2133\/dmpk.19.327","article-title":"In silico approaches for predicting ADME properties of drugs","volume":"19","author":"Yamashita","year":"2004","journal-title":"Drug Metab Phamacokin"},{"key":"10.1016\/j.jbi.2009.05.010_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2005.09.004","article-title":"In vitro cytochrome P450 inhibition data and the prediction of drug\u2013drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach","volume":"78","author":"Obach","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jbi.2009.05.010_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00003088-200140090-00001","article-title":"Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies","volume":"40","author":"Bonnabry","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbi.2009.05.010_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1874073100903010008","article-title":"An experimental pharmacokinetic computer program to predict potential drug\u2013drug interactions","volume":"3","author":"Zvada","year":"2009","journal-title":"Open Drug Metab J"},{"key":"10.1016\/j.jbi.2009.05.010_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.tpj.6500035","article-title":"Integrating genotype and phenotype information: an overview of the PharmGKB project","volume":"1","author":"Klein","year":"2001","journal-title":"Pharmacogen J"},{"key":"10.1016\/j.jbi.2009.05.010_bib27","doi-asserted-by":"crossref","unstructured":"Karp P, Paley S, Krieger C, Zhang P. An evidence ontology for use in pathway\/genome databases. In: Pacific symposium on biocomputing 2004; 2004. p. 190\u2013201.","DOI":"10.1142\/9789812704856_0019"},{"issue":"1","key":"10.1016\/j.jbi.2009.05.010_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cognition.2005.09.006","article-title":"Comparison of confirmation measures","volume":"103","author":"Tentori","year":"2007","journal-title":"Cognition"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0009-9236(96)90179-4","article-title":"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism","volume":"59","author":"Yasui","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002130050715","article-title":"Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam","volume":"139","author":"Yasui","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0009-9236(98)90172-2","article-title":"Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences","volume":"64","author":"Greenblatt","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jbi.2009.05.010_bib32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/01213011-199912000-00007","article-title":"Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine","volume":"9","author":"Schmider","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10.1016\/j.jbi.2009.05.010_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.jcp.0000104908.75206.26","article-title":"Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers","volume":"24","author":"DeVane","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.jbi.2009.05.010_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00004714-199512000-00003","article-title":"Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam","volume":"15","author":"Greene","year":"1995","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/009127009903900510","article-title":"Erythromycin coadministration increases plasma atorvastatin concentrations","volume":"39","author":"Siedlik","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jbi.2009.05.010_bib36","unstructured":"Teva, nefazodone hydrochloride (Nefazodone Hydrochloride) tablet. FDA-approved drug product labeling; 2006. Last accessed on DailyMed 04\/21\/2009."},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib37","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/00912700222011373","article-title":"A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers","volume":"42","author":"Amsden","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jbi.2009.05.010_bib38","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jbi.2009.05.010_bib39","unstructured":"Abbott. Biaxin filmtab (clarithromycin) tablet, film coated. FDA-approved drug product labeling; 2007. Last accessed on DailyMed 05\/29\/2008."},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(98)90067-4","article-title":"The interaction of diltiazem with lovastatin and pravastatin","volume":"64","author":"Azie","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jbi.2009.05.010_bib41","unstructured":"Biovail. cardizem (diltiazem hydrochloride) tablet, coated. FDA-approved drug product labeling; 2006. Last accessed on DailyMed 04\/21\/2009."},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1067\/mcp.2000.104609","article-title":"The interaction of diltiazem with simvastatin","volume":"67","author":"Mousa","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(96)90103-4","article-title":"Diltiazem enhances the effects of triazolam by inhibiting its metabolism","volume":"59","author":"Varhe","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jbi.2009.05.010_bib45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-9236(98)90151-5","article-title":"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s002280050223","article-title":"Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam","volume":"51","author":"Ahonen","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002280000127","article-title":"Effect of fluconazole on plasma fluvastatin and pravastatin concentrations","volume":"56","author":"Kantola","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1067\/mcp.2000.110537","article-title":"Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin","volume":"68","author":"Mazzu","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jbi.2009.05.010_bib49","unstructured":"Janssen. sporanox (itraconazole) capsule. FDA-approved drug product labeling; 2008. Last accessed on DailyMed 05\/16\/2008."},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib50","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jbi.2009.05.010_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jbi.2009.05.010_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0091270005284854","article-title":"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin","volume":"46","author":"Gurley","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/clpt.1993.25","article-title":"A potentially hazardous interaction between erythromycin and midazolam","volume":"53","author":"Olkkola","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib54","first-page":"511","article-title":";The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"82","author":"Olkkola","year":"1996","journal-title":"Anesth Analg"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jbi.2009.05.010_bib56","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","article-title":"Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone","volume":"43","author":"Lam","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004714-198610000-00008","article-title":"A pharmacokinetic drug interaction between erythromycin and triazolam","volume":"6","author":"Phillips","year":"1986","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jbi.2009.05.010_bib58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2125.1996.03189.x","article-title":"Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism","volume":"41","author":"Varhe","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jbi.2009.05.010_bib59","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0009-9236(96)90059-4","article-title":"The effect of ingestion time interval on the interaction between itraconazole and triazolam","volume":"60","author":"Neuvonen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"6 Pt. 1","key":"10.1016\/j.jbi.2009.05.010_bib60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.1994.184","article-title":"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole","volume":"56","author":"Varhe","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jbi.2009.05.010_bib61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0022-3565(25)12284-2","article-title":"Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole","volume":"276","author":"von Moltke","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.jbi.2009.05.010_bib62","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00004714-199510000-00003","article-title":"Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam","volume":"15","author":"Barbhaiya","year":"1995","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.jbi.2009.05.010_bib63","doi-asserted-by":"crossref","first-page":"W31","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w1","article-title":"Potentially fatal interaction between diltiazem and statins","volume":"140","author":"Gladding","year":"2004","journal-title":"Ann Intern Med"},{"issue":"7\u20138","key":"10.1016\/j.jbi.2009.05.010_bib64","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.1C467","article-title":"Simvastatin\u2013fluconazole causing rhabdomyolysis","volume":"37","author":"Shaukat","year":"2003","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Biomedical Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/2.zoppoz.workers.dev:443\/https\/api.elsevier.com\/content\/article\/PII:S1532046409000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/2.zoppoz.workers.dev:443\/https\/api.elsevier.com\/content\/article\/PII:S1532046409000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:29:48Z","timestamp":1739165388000},"score":1,"resource":{"primary":{"URL":"https:\/\/2.zoppoz.workers.dev:443\/https\/linkinghub.elsevier.com\/retrieve\/pii\/S1532046409000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1532046409000823"],"URL":"https:\/\/2.zoppoz.workers.dev:443\/https\/doi.org\/10.1016\/j.jbi.2009.05.010","relation":{},"ISSN":["1532-0464"],"issn-type":[{"type":"print","value":"1532-0464"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}